about
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeEuropean perspective on multiple myeloma treatment strategies in 2014Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study.Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment.Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study.Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.[Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group].CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable diseaseEuropean perspective on multiple myeloma treatment strategies: update following recent congressesAnalysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study.Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens".Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.Clinical treatment of newly diagnosed multiple myeloma.Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?Which therapies will move to the front line for multiple myeloma?Immunotherapy for the treatment of Hodgkin lymphoma.Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation.Quality control of bacterial contamination in autologous peripheral blood stem cells for transplantation.Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.Genomic analysis of high-risk smoldering multiple myeloma.Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors.DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma?Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia.
P50
Q26782868-041EB55A-84A4-4B28-986F-13AC091262E9Q27005966-FD7ABEC4-FC64-4AA9-B2DA-94A42A1F45FDQ33376498-C0EB7995-86A2-4020-A365-A7DF9DB7876CQ33380423-AA5E11C7-A71D-4E39-B651-C27E46EC66F2Q33383214-71F7A648-B9AE-4C76-AAED-967A3E37E7CEQ33389982-34405A55-923B-4093-9359-3FC18A46CD1CQ33392225-D897B936-1E4D-47C6-A59C-3472DCEFECE4Q33417762-26E61C02-A963-4869-AC95-A96C87331409Q33418938-D17B295D-9F79-4DB3-A386-BEE806B81E20Q35266066-C19B4DFD-385B-4EC3-BC23-F7DC187A06E5Q35944707-BF9B6015-AA36-4F57-B996-BC33C7E41F47Q35989943-0C532437-6A88-478C-8AC9-35805D5C9BF7Q36498366-BBA98739-F8B9-4591-B508-5E043BE56F17Q36708998-ADC8AD5F-F126-4C3F-9CE4-A2651A8C7FB0Q36969778-D2BDA62C-9B94-4BB0-BBA9-6D6F87D272C6Q36989576-F6F8E0D9-30E4-416C-BB26-B66A4C117FB1Q37216380-1FAC711A-F6F7-4DCB-BB16-C7FAFBB87133Q37334978-E6869D21-619B-4F77-8759-A0BB49228840Q37734031-7DCBF5AA-B979-42D2-A9C5-3BB9959E8C6CQ38209433-1B098385-656C-49A5-9D33-0A4E13D1D3EEQ38411566-9D49E5A3-77D3-4DE3-8A08-B7B8AFCE92DBQ38413040-BED08FD3-B3AC-4AF8-B636-C63A44886425Q38548134-F985FE13-77CA-4A18-8430-589DEC703EAEQ38578071-DE16B05F-7AA1-4E41-86B5-64FEB2447249Q38597127-66D515C0-AC4C-49F8-A0D8-8006DC46325CQ38733592-4F5F8F1F-EAED-4EA7-98E0-D75817CF1CF9Q38737641-B0FCA8B7-8DDB-4490-ACC1-3DFA08F6C3C4Q38842962-D2CC698D-04FE-4F41-9E57-78FF45CE3579Q40211335-0343CC2F-5BE0-4F20-B52D-E5D59998857BQ40394880-1D701801-9D59-4D07-B1A3-2C960E21FEB5Q40432531-D5C827F6-8A3E-41A6-A4E3-1093AC71A466Q40523936-1FBA4DFD-A737-402D-80BD-B9F199ED3940Q41010737-FFDEACCB-4381-439D-9D92-8D939EAEC451Q41602673-9AFA8FB5-F183-4F5A-9293-A331073274B4Q41756273-B4913BBB-7BA0-4A54-A7A3-AED04BD5B380Q41847877-3B9D580D-17B3-4EDF-8F84-3AA0483AF2B4Q42518728-605E06EE-3171-4039-B603-0DC3994EBFCAQ42814336-5E8F96FA-D180-46AA-9ECD-658CCF39C3B1Q42956254-3C8794A3-9AD4-40D1-AB2D-943244C03BB2Q43017863-CA8086EE-5A52-4BE8-8084-85D7320F0950
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Javier de la Rubia
@ast
Javier de la Rubia
@en
Javier de la Rubia
@es
Javier de la Rubia
@nl
Javier de la Rubia
@sl
type
label
Javier de la Rubia
@ast
Javier de la Rubia
@en
Javier de la Rubia
@es
Javier de la Rubia
@nl
Javier de la Rubia
@sl
prefLabel
Javier de la Rubia
@ast
Javier de la Rubia
@en
Javier de la Rubia
@es
Javier de la Rubia
@nl
Javier de la Rubia
@sl
P106
P21
P31
P496
0000-0002-8354-768X